ConcertAI and Caris Life Sciences are partnering to create a database for oncology research, aiming to provide valuable insights to advance precision medicine, clinical trial management, and therapeutic development. The collaboration will leverage their clinical, molecular, and multimodal data to support academic and biopharma researchers. The database will facilitate a deeper understanding of cancer biology and enable novel clinical approaches. Both companies have secured significant investments in recent years, indicating the importance of their contributions to the field.
ConcertAI and Caris Life Sciences have announced an expanded partnership to collaborate on oncology research. The objective is to develop a comprehensive database that will provide valuable insights for academic and biopharma researchers, thereby advancing cancer-focused research.
ConcertAI is a prominent real-world data and AI company that caters to healthcare providers and life science organizations. On the other hand, Caris Life Sciences specializes in whole exome and whole transcriptome sequencing, utilizing AI modeling in its clinical-genomic database to aid researchers in understanding the complex molecular nature of diseases.
Through their joint efforts, ConcertAI and Caris Life Sciences will leverage their clinical, molecular, and multimodal data to build a database. This resource will enable academics and biopharma researchers to gain critical insights into precision medicine, clinical trial management, and therapeutic development within the field of oncology.
Dr. Jeff Elton, CEO of ConcertAI, emphasized the significance of this partnership, stating, “By creating innovative research assets on a large scale, integrating cutting-edge technologies and talent, we can collaborate with academic researchers and biopharma innovators to accelerate our understanding of cancer biology. This will facilitate the translation of these insights into clinical practice and enable novel approaches to clinical development.”
The ultimate goal of this collaboration is to provide broad access to extensive and comprehensive data, surpassing the capabilities of most public or private initiatives. This will be particularly beneficial for cancer patients, including those who currently have limited therapeutic options available to them.
Caris Life Sciences and ConcertAI initially joined forces in January to leverage their respective oncology capabilities and drive therapeutic research and drug development. ConcertAI, a part of SymphonyAI, an artificial intelligence company that spans various business sectors, acquired imaging AI provider TeraRecon in 2020, now operating as a ConcertAI subsidiary.
Over the years, ConcertAI has established numerous partnerships. It has collaborated with Janssen Research & Development to enhance study design and diversify clinical trials, as well as with Bristol-Myers Squibb and Pfizer to support precision oncology treatment research.
Both ConcertAI and Caris Life Sciences have attracted significant investments in recent years. In 2022, ConcertAI, formerly known as Concerto HealthAI, secured $150 million in Series C funding, just two years after closing $150 million in Series B financing.
Caris Life Sciences raised $400 million in debt financing in January, bringing its total capital raised to over $1.7 billion. In 2021, the company obtained $830 million in growth equity capital and received a $235 million equity investment in 2020.
